Measured human results come first
CJC-1295 Ipamorelin vs Tesamorelin: which has human proof?
Tesamorelin has approval and fair human trials. The two-drug pair has no measured human result of its own.
How does the human proof differ?
CJC-1295 Ipamorelin vs tesamorelin is mainly a question about proof. Tesamorelin has fair human trials.
Tesamorelin also has approval for one health problem. The two-drug pair has neither.
Tesamorelin and CJC-1295 can each prompt more growth hormone. Ipamorelin also acts like a stomach hormone tied to hunger.
Tesamorelin trials measured belly fat, liver fat, and lean body weight. The pair has no such results.
Proof for the pair comes from three separate places. One tested the long drug in people, another tested ipamorelin in animals, and older work tested related pairs.
Some studies also measured IGF-1, a hormone made by the liver. Each number below stays with the drug and people tested.
What did tesamorelin trials measure in people?
Tesamorelin has human proof that the pair lacks. A 2026 review combined five fair trials.
Belly scans showed an average deep-fat drop of 27.71 cm² on one slice. The review didn't turn that area into waist inches or a change people could see.
Liver fat fell by 4.28%. The scan number alone doesn't say how a person felt.
Lean body weight rose 1.42 kilograms. IGF-1, a hormone made by the liver, rose too.
The trials showed no grave harm and no blood-sugar change [7]. Those are measured human results.
Tesamorelin acts like the same brain hormone as CJC-1295. That helps explain one part of the pair.
Tesamorelin cannot show what ipamorelin adds. A result for one drug tells us nothing certain about a pair.
Which findings apply to the pair, and which don't?
Long CJC-1295 raised growth hormone and IGF-1 in healthy adults [1]. Animal tests found growth-hormone release after ipamorelin [2].
Animals given ipamorelin had no rise in either stress hormone. Older human and cell work found larger bursts from related pairs [3][4].
The findings came from different drugs and test subjects. The pair itself never received a fair test.
No CJC-1295 Ipamorelin study measured belly fat or lean body weight. Results for the pair remain unknown.
Mice add one warning. Ipamorelin raised hunger and body fat in the mice [8].
A mouse result doesn't prove weight gain in people. The result does weaken any sure fat-loss claim.
A drug's action can explain why a change might happen. Only a fair trial can show whether the change occurred.
What does the proof mean for you?
Tesamorelin has stronger proof. It has fair trials, measured results, and an approval [7].
CJC-1295 and ipamorelin send two different hormone messages [2][3]. A larger growth-hormone burst doesn't equal a health gain.
Blood sugar may rise with either choice. The body may also keep extra water, causing swelling [6].
Tesamorelin is one approved drug with measured body changes. The pair remains an untested lab mix.
Ipamorelin vs sermorelin compares ipamorelin with another short-acting drug. That comparison answers a different question.